C12N 2330/51
Specially adapted vectors
C12N2330/51 (Specially adapted vectors) appears on 400 US grants and 767 published applications in this corpus.
Search patents in C12N- Granted patents
- 400
- Published applications
- 767
- Assignees
- 372
- Inventors
- 1,408
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 3 |
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 5 |
| 2010 | 2 | 16 |
| 2011 | 3 | 15 |
| 2012 | 6 | 24 |
| 2013 | 10 | 21 |
| 2014 | 12 | 31 |
| 2015 | 13 | 21 |
| 2016 | 18 | 40 |
| 2017 | 20 | 47 |
| 2018 | 25 | 57 |
| 2019 | 40 | 86 |
| 2020 | 27 | 64 |
| 2021 | 43 | 60 |
| 2022 | 40 | 68 |
| 2023 | 34 | 66 |
| 2024 | 33 | 60 |
| 2025 | 39 | 48 |
| 2026 | 34 | 29 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vectors and compositions for treating hemoglobinopathies11 Aug 2026US 12,703,864 B2Children's Medical Center Corporation
- Viral vectors for treating Parkinson's disease4 Aug 2026US 12,697,360 B2American Gene Technologies International Inc.
- RAAV-based compositions and methods for treating amyotrophic lateral sclerosis23 Jun 2026US 12,662,669 B2University of Massachusetts
- Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers16 Jun 2026US 12,653,851 B2Hangzhou Converd Co., Ltd.
- Targeting peptides for directing adeno-associated viruses (AAVs)16 Jun 2026US 12,653,904 B2California Institute of Technology
- Analytical device for real time luminescence during temperature hold and ramp as used in real time cellular thermal shift assay1 Oct 2026US 2026/0297593 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Generation of neurons by reprogramming of oligodendrocytes and oligodendrocyte precursor cells3 Sep 2026US 2026/0256853 A1The University of North Carolina at Chapel Hill
- Compositions of Asymmetric Interfering RNA and Uses Thereof3 Sep 2026US 2026/0258412 A11Globe Health Institute LLC
- Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs3 Sep 2026US 2026/0258419 A1Research Institute At Nationwide Children's Hospital
- Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)27 Aug 2026US 2026/0250769 A1Fred Hutchinson Cancer Center
Most cited
By later US patents
- In vivo production of small interfering RNAS that mediate gene silencing253US 7,691,995 B2University of Massachusetts · 2010
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- Compositions and methods for silencing ebola virus gene expression98US 9,187,748 B22015
- Viral vectors for the treatment of diabetes86US 11,085,055 B22021
- Composition for regulating production of interfering ribonucleic acid76US 12,134,770 B1Wyvern Pharmaceuticals Inc. · 2024